| dalfampridine / Generic mfg. |
ACTRN12613000439741: A clinical and electrophysiological study of the effects of
4-aminopyridine on upper limb impairment in Multiple Sclerosis
|
|
|
| Not yet recruiting | 4 | 30 | | | Austin Health, National Health and Medical Research Council - funding the study doctor via a postgraduate scholarship. | Multiple Sclerosis | | | | |
ACTRN12613000331730: A placebo-controlled, randomized, double-blind trial of the effects of modified release 4-aminopyridine on upper limb impairment in Multiple Sclerosis |
|
|
| Not yet recruiting | 4 | 60 | | | Austin Health, Biogen Idec, National Health and Medical Research Council (NHMRC) | Multiple Sclerosis | | | | |
2013-001409-10: Fampyra and T cell Immunity in Multiple Sclerosis; a study of the Fampyra induced immunomodulatory T cell responses in MS |
|
|
| Ongoing | 4 | 40 | Europe | Fampyra, Tablet, Fampyra | Odense University Hospital, Odense University Hospital | Multiple Sclerosis, Multiple Sclerosis, Diseases [C] - Nervous System Diseases [C10] | | | | |
2014-003498-41: Effects of dalfampridine on mobility in the context of daily life |
|
|
| Ongoing | 4 | 51 | Europe | Tablet, Fampyra | Medical University of Vienna, Medical University of Vienna, Department of Neurology, Biogen Idec | Motor behaviour and cognition in multiple sclerosis patients, Motor behaviour and cognition in multiple sclerosis patients, Diseases [C] - Nervous System Diseases [C10] | | | | |
2014-004650-34: New strategies for diagnostic, therapeutic and clinical care in neurological diseases Nuove strategie per la diagnosi, la terapia e la gestione medica nelle malattie neurologiche |
|
|
| Ongoing | 4 | 45 | Europe | Tablet, FAMPYRA - 10 MG - COMPRESSA A RILASCIO PROLUNGATO - USO ORALE - FLACONE (HDPE) 56 COMPRESSE (4 FLACONI DA 14) | IRCCS FONDAZIONE ISTITUTO NEUROLOGICO NAZIONALE C. MONDINO, Ministero della Salute | Multiple sclerosis with cerebellar ataxia Sclerosi multipla con atassia cerebellare, Multiple sclerosis Sclerosi multipla, Diseases [C] - Nervous System Diseases [C10] | | | | |
AmpPT, NCT06136728: Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis |
|
|
| Not yet recruiting | 4 | 48 | US | Dalfampridine 10 MG [Ampyra], Ampyra, Physical therapy, Dalfampridine plus physical therapy, Combined drug and behavioral | MGH Institute of Health Professions | Multiple Sclerosis | 01/26 | 06/26 | | |
2012-005076-34: Prolonged-release oral Fampridine in Multiple Sclerosis: effects on clinical, neurophysiological and quantified gait analysis parameters.A cross-over, double-blinded, placebo-controlled study. Fampridine à liberation prolongée dans la sclérose en plaque: les effets sur les paramètres cliniques, neurophysiologiques et de l’analyse quantifiée de la marche.Une étude en cross-over et double aveugle, contrôlée par placebo. |
|
|
| Ongoing | 3 | 110 | Europe | Fampridine, BIIB041, Prolonged-release tablet, Fampyra | Cliniques Universitaires Saint-Luc, Neurologie, Biogen Idec Research Limited | Multiple Sclerosis Sclérose en Plaques, Multiple Sclerosis Sclérose en Plaques, Diseases [C] - Nervous System Diseases [C10] | | | | |
2012-005312-26: Analysis of the effectiveness of the drug Fampyra® in patients with gait disorder |
|
|
| Ongoing | 3 | 75 | Europe | Fampyra, Fampyra | Hospital of the University of Munich, Grosshadern, Biogen Idec GmbH | cerebellar gait disorder, cerebellar ataxia, sensorimotor adaption and ocular motor disorders, postural sway, dysarthria | | | | |
2013-000107-17: Comparsion of the therapy with Fampyra and Acemit in patients with episodic ataxia type 2 |
|
|
| Ongoing | 3 | 30 | Europe | Fampyra TM, Acemit TM, Fampyra TM, Acemit TM | Hospital of the University of Munich, Grosshadern, Bundesministerium für Bildung und Forschung (BMBF), Biogen Idec International GmbH | Familial episodic ataxia (EA) represents a genetically and phenotypically diverse group of rare autosomal dominant hereditary disorders characterized by episodes of imbalance and incoordination that are variably associated with interictal neurological signs and typically triggered by physical exertion and emotional stress. Episodic ataxia type 2 (EA2) with associated interictal nystagmus and other ocular motor abnormalities is the most common and the best characterized of all EA syndromes. | | | | |
2021-003677-66: Clemastine fumarate as a treament for eye movement disorders in patients with multiple sclerosis Clemastine fumaraat als behandeling voor een stoornis in de oogbewegingen bij patiënten met multiple sclerose |
|
|
| Not yet recruiting | 3 | 80 | Europe | Clemastine fumarate, Fampridine, Tablet, Clemastine Milstein 1 mg, tabletten, Fampyra 10 mg prolonged-release tablets | Amsterdam University Medical Center, Stichting VUmc Fonds | Multiple sclerosis (MS)Internuclear ophthalmoparesis (INO) Multiple sclerose (MS)Internucleaire oftalmoplegie (INO), Multiple sclerosis (MS)Eye movement disorder Multiple scleroseOogbewegingsstoornis, Diseases [C] - Nervous System Diseases [C10] | | | | |
NCT03899584: High Doses of 4-aminopyridine in Clinically Complete Chronic Spinal Cord Injury Patients. |
|
|
| Active, not recruiting | 3 | 150 | RoW | 4-Aminopyridine, 4-AP, Placebo oral capsule, Microcrystalline cellulose | Coordinación de Investigación en Salud, Mexico | Spinal Cord Injuries, Chronic | 12/22 | 12/23 | | |
| Not yet recruiting | 3 | 68 | NA | 4-Aminopyridine, 4AP, Placebo | University of Arizona, National Institute of Neurological Disorders and Stroke (NINDS) | Peripheral Nerve Injury, Crush Injury | 12/27 | 07/28 | | |
NCT05859802: Effects of Physical Therapy and Dalfampridine on Functional Mobility in Non Ambulatory Persons With Multiple Sclerosis |
|
|
| Completed | 2/3 | 35 | NA | Dalfampridine Pill, Physical Therapy, Placebo | D'Youville College, Acorda Therapeutics, University at Buffalo | Multiple Sclerosis | 03/15 | 01/16 | | |
| Active, not recruiting | 2/3 | 70 | US | 4-Aminopyridine, 4-AP, Fampridine, Placebo | John Elfar, University of Arizona | Nerve Injury, Prostate Cancer | 07/24 | 08/25 | | |
| Not yet recruiting | 2/3 | 160 | NA | 4-Aminopyridine, Placebo | John Elfar | Compression Neuropathy, Carpal Tunnel Syndrome | 12/27 | 07/28 | | |
ACTRN12611000800921: Does Fampridine improve fatigue in patients with chronic inflammatory demyelinating polyneuropathy (CIDP). |
|
|
| Not yet recruiting | 2 | 20 | | | Univeristy of New South Wales, Biogen Idec international GmbH. | chronic inflammatory demyelinating polyneuropathy (CIDP). | | | | |
2012-000287-17: functional MRI study to evaluate improvement of hand performance after combined motor exercise and aminopiridine assumption Studio di risonanza Magnetica funzionale per valutare il miglioramento della performance motoria della mano dopo esercizio fisico associato ad assunzione di aminopiridina |
|
|
| Ongoing | 2 | 100 | Europe | Prolonged-release tablet, FAMPYRA | FONDAZIONE SANTA LUCIA, Ministero della Salute | Patients with MS, without relevant medical conditions, with right upper limb impairment assessed by a hand dexterity test will be included.Patients will be in a non-active phase of the disease and under a stable pharmacological treatment.They will not be included if they have received physiotherapy in the previous few months. Healthy volunteers will be recruited if they have no relevant medical condition and no contraindication to perform a MRI scan. Verranno inclusi pazienti con SM, senza altre patologie di rilievo, e con impaccio motorio dell’arto superiore dx quantificato da test di destrezza manuale. I pazienti saranno in fase non attiva di malattia e in trattamento farmacologico stabile nel periodo precedente e in corso di studio. Non dovranno aver effettuato fisioterapia nei mesi precedenti. I volontari sani non dovranno presentare patologie di rilievo e controindicazioni alla RM., MS patients with right upper limb impaired, non-active phase, stable pharmacological treatment and no physiotherapy.Healthy volunteers without medical condition and contraindication to MRI. Pazienti con SM e disabilita' in arto superiore dx,in fase non attiva,in terapia farmacologica stabile,non in fisioterapia.I volontari sani senza malattie di rilievo,ne' controindicazioni aRM, Diseases [C] - Nervous System Diseases [C10] | | | | |
2015-000182-31: Study to evaluate the effects of fampridine in patients with multiple sclerosis and eye movement abnormality |
|
|
| Ongoing | 2 | 24 | Europe | Fampyra 10 mg prolonged-release tablets, Fampyra 10 mg prolonged-release tablets | CHDR, CHDR, Biogen Idec Ltd | Multiple sclerosis (MS) and a unilateral or bilateral internuclear ophthalmoplegia (INO) | | | | |
2020-002438-34: Fampridine for treatment of functional disability in patients with immune mediated polyneuropathy |
|
|
| Not yet recruiting | 2 | 40 | Europe | Fampyra, Tablet, Fampyra | Department of Neurology, Odense University Hospital, Novo Nordisk Foundation | Chronic inflammatory demyelinating polyneuropathy, Immune mediated polyneuropathy, Diseases [C] - Nervous System Diseases [C10] | | | | |
| Not yet recruiting | 2 | 68 | US | 4-Aminopyridine, 4AP, dalfampridine, Placebo | John Elfar | Wounds, Wound of Skin, Wound Heal, Wounds and Injuries | 09/27 | 03/28 | | |
ACTRN12617001339347: Effects of lithium and fampridine on electroencephalography profiles in healthy volunteers |
|
|
| Not yet recruiting | 1 | 24 | | | University of Otago, University of Otago | Bipolar Disorder | | | | |
ACTRN12617001339347p: Effects of lithium and fampridine on electroencephalography profiles in healthy volunteers |
|
|
| Not yet recruiting | 1 | 24 | | | University of Otago, University of Otago | Bipolar Disorder | | | | |
| Recruiting | 1 | 20 | Canada | Fampridine SR | Courtney Casserly | Optic Neuritis | 12/23 | 01/24 | | |
| Recruiting | 1 | 44 | US | Dalfampridine, 4-AP, Placebo drug, STDP stimulation, spike timing dependent plasticity, Exercise training | Shirley Ryan AbilityLab, National Institute of Neurological Disorders and Stroke (NINDS) | Spinal Cord Injury | 06/24 | 06/25 | | |
NCT02868567: Use of Dalfampridine in Primary Lateral Sclerosis |
|
|
| Active, not recruiting | 1 | 35 | US | dalfampridine, ampyra | Hospital for Special Surgery, New York | Motor Neuron Disease, Upper | 07/24 | 07/24 | | |
RETROFAM, NCT02966808: Retrospective Observational Study About Long-term Effect of Fampridine in Patients With Multiple Sclerosis |
|
|
| Recruiting | N/A | 50 | Europe | cognitive and behavioural questionnaires, PASAT, SDMT, MSQoL-54, MSFIS, T25WF, MSWS12 | Hospital General Universitario Gregorio Marañon | Multiple Sclerosis | 12/21 | 12/21 | | |
NCT05730738: Dalfampridine in Egyptian Patients With Multiple Sclerosis |
|
|
| Recruiting | N/A | 100 | RoW | Dalfampridine ER, 10 Mg Oral Tablet, Extended Release, Placebo | Ain Shams University | Multiple Sclerosis | 12/23 | 12/24 | | |
FamC, NCT05274477: Influence of Fampridine on Working Memory in Individuals With Post COVID-19 Condition With Subjective Cognitive Impairment |
|
|
| Active, not recruiting | N/A | 44 | Europe | Fampridine SR, Placebo | Prof. Dominique de Quervain, MD, Clinical Trial Unit, University Hospital Basel, Switzerland, University Hospital, Basel, Switzerland | Working Memory, Post-covid-19 | 06/24 | 06/24 | | |